A disorder of neuromuscular transmission that occurs in a minority of newborns born to women with myasthenia gravis. Clinical features are usually present at birth or develop in the first 3 days of li...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on neonatal myasthenia gravis is limited due to its rarity and the fact that it affects a small number of newborns. As a result, systematic clinical studies have been scarce, making it challenging to gather comprehensive data. Additionally, the clinical features may vary significantly among affected infants, further complicating the characterization of the condition.
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
There are several orphan drugs approved for use in conditions related to myasthenia gravis, including eculizumab and pyridostigmine bromide. Additionally, there are numerous drugs in development, such as autologous anti-CD19 CAR T cell immunotherapy and neostigmine methylsulfate. Currently, there are 10 active clinical trials exploring various aspects of neonatal myasthenia gravis. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neonatal%20myasthenia%20gravis.
Actionable guidance for navigating care for neonatal myasthenia gravis
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on neonatal myasthenia gravis is limited due to its rarity and the fact that it affects a small number of newborns. As a result, systematic clinical studies have been scarce, making it challenging to gather comprehensive data. Additionally, the clinical features may vary significantly among affected infants, further complicating the characterization of the condition.
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
There are several orphan drugs approved for use in conditions related to myasthenia gravis, including eculizumab and pyridostigmine bromide. Additionally, there are numerous drugs in development, such as autologous anti-CD19 CAR T cell immunotherapy and neostigmine methylsulfate. Currently, there are 10 active clinical trials exploring various aspects of neonatal myasthenia gravis. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neonatal%20myasthenia%20gravis.
Actionable guidance for navigating care for neonatal myasthenia gravis
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on neonatal myasthenia gravis is limited due to its rarity and the fact that it affects a small number of newborns. As a result, systematic clinical studies have been scarce, making it challenging to gather comprehensive data. Additionally, the clinical features may vary significantly among affected infants, further complicating the characterization of the condition.
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
There are several orphan drugs approved for use in conditions related to myasthenia gravis, including eculizumab and pyridostigmine bromide. Additionally, there are numerous drugs in development, such as autologous anti-CD19 CAR T cell immunotherapy and neostigmine methylsulfate. Currently, there are 10 active clinical trials exploring various aspects of neonatal myasthenia gravis. You can find more information about these trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neonatal%20myasthenia%20gravis.
Actionable guidance for navigating care for neonatal myasthenia gravis
To navigate neonatal myasthenia gravis, it is crucial to consult with a pediatric neurologist who has experience in neuromuscular disorders. They can provide tailored care and management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. While no patient organizations are currently identified, participating in clinical trials may also provide access to cutting-edge treatments and support networks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.